Shirya Rashid1, Hagai Tavori2, Patrick E Brown2, MacRae F Linton2, Jane He2, Ilaria Giunzioni2, Sergio Fazio2. 1. From the Department of Pharmacology, Dalhousie University, Halifax, NS, and Saint John, NB, Canada (S.R.); Department of Medicine, Section of Cardiovascular Disease Prevention, Vanderbilt University, Nashville, TN (H.T., M.F.L., J.H., I.G., S.F.); Oregon Health and Science University, Portland (H.T., I.G.); and Department of Biostatistics, Faculty of Medicine, University of Toronto and Cancer Care Ontario, Toronto, ON, Canada (P.E.B.). shirya.rashid@Dal.ca. 2. From the Department of Pharmacology, Dalhousie University, Halifax, NS, and Saint John, NB, Canada (S.R.); Department of Medicine, Section of Cardiovascular Disease Prevention, Vanderbilt University, Nashville, TN (H.T., M.F.L., J.H., I.G., S.F.); Oregon Health and Science University, Portland (H.T., I.G.); and Department of Biostatistics, Faculty of Medicine, University of Toronto and Cancer Care Ontario, Toronto, ON, Canada (P.E.B.).
Abstract
BACKGROUND: Proprotein convertase subtilisin kexin type 9 (PCSK9) promotes the degradation of the low-density lipoprotein (LDL) receptor (LDLR), and its deficiency in humans results in low plasma LDL cholesterol and protection against coronary heart disease. Recent evidence indicates that PCSK9 also modulates the metabolism of triglyceride-rich apolipoprotein B (apoB) lipoproteins, another important coronary heart disease risk factor. Here, we studied the effects of physiological levels of PCSK9 on intestinal triglyceride-rich apoB lipoprotein production and elucidated for the first time the cellular and molecular mechanisms involved. METHODS AND RESULTS: Treatment of human enterocytes (CaCo-2 cells) with recombinant human PCSK9 (10 μg/mL for 24 hours) increased cellular and secreted apoB48 and apoB100 by 40% to 55% each (P<0.01 versus untreated cells), whereas short-term deletion of PCSK9 expression reversed this effect. PCSK9 stimulation of apoB was due to a 1.5-fold increase in apoB mRNA (P<0.01) and to enhanced apoB protein stability through both LDLR-dependent and LDLR-independent mechanisms. PCSK9 decreased LDLR protein (P<0.01) and increased cellular apoB stability via activation of microsomal triglyceride transfer protein. PCSK9 also increased levels of the lipid-generating enzymes FAS, SCD, and DGAT2 (P<0.05). In mice, human PCSK9 at physiological levels increased intestinal microsomal triglyceride transfer protein levels and activity regardless of LDLR expression. CONCLUSIONS: PCSK9 markedly increases intestinal triglyceride-rich apoB production through mechanisms mediated in part by transcriptional effects on apoB, microsomal triglyceride transfer protein, and lipogenic genes and in part by posttranscriptional effects on the LDLR and microsomal triglyceride transfer protein. These findings indicate that targeted PCSK9-based therapies may also be effective in the management of postprandial hypertriglyceridemia.
BACKGROUND:Proprotein convertase subtilisin kexin type 9 (PCSK9) promotes the degradation of the low-density lipoprotein (LDL) receptor (LDLR), and its deficiency in humans results in low plasma LDL cholesterol and protection against coronary heart disease. Recent evidence indicates that PCSK9 also modulates the metabolism of triglyceride-rich apolipoprotein B (apoB) lipoproteins, another important coronary heart disease risk factor. Here, we studied the effects of physiological levels of PCSK9 on intestinal triglyceride-rich apoB lipoprotein production and elucidated for the first time the cellular and molecular mechanisms involved. METHODS AND RESULTS: Treatment of human enterocytes (CaCo-2 cells) with recombinant humanPCSK9 (10 μg/mL for 24 hours) increased cellular and secreted apoB48 and apoB100 by 40% to 55% each (P<0.01 versus untreated cells), whereas short-term deletion of PCSK9 expression reversed this effect. PCSK9 stimulation of apoB was due to a 1.5-fold increase in apoB mRNA (P<0.01) and to enhanced apoB protein stability through both LDLR-dependent and LDLR-independent mechanisms. PCSK9 decreased LDLR protein (P<0.01) and increased cellular apoB stability via activation of microsomal triglyceride transfer protein. PCSK9 also increased levels of the lipid-generating enzymes FAS, SCD, and DGAT2 (P<0.05). In mice, humanPCSK9 at physiological levels increased intestinal microsomal triglyceride transfer protein levels and activity regardless of LDLR expression. CONCLUSIONS:PCSK9 markedly increases intestinal triglyceride-rich apoB production through mechanisms mediated in part by transcriptional effects on apoB, microsomal triglyceride transfer protein, and lipogenic genes and in part by posttranscriptional effects on the LDLR and microsomal triglyceride transfer protein. These findings indicate that targeted PCSK9-based therapies may also be effective in the management of postprandial hypertriglyceridemia.
Authors: Margarita Garcia-Calvo; JeanMarie Lisnock; Herbert G Bull; Brian E Hawes; Duane A Burnett; Matthew P Braun; James H Crona; Harry R Davis; Dennis C Dean; Patricia A Detmers; Michael P Graziano; Meredith Hughes; D Euan Macintyre; Anthony Ogawa; Kim A O'neill; Sai Prasad N Iyer; Diane E Shevell; Marsha M Smith; Yui S Tang; Amanda M Makarewicz; Feroze Ujjainwalla; Scott W Altmann; Kevin T Chapman; Nancy A Thornberry Journal: Proc Natl Acad Sci U S A Date: 2005-05-31 Impact factor: 11.205
Authors: Ahmad F Hedayat; Kyoung-Ha Park; Taek-Geun Kwon; John R Woollard; Kai Jiang; Daniel F Carlson; Amir Lerman; Lilach O Lerman Journal: Transl Res Date: 2017-11-03 Impact factor: 7.012
Authors: Hong Lu; Deborah A Howatt; Anju Balakrishnan; Mark J Graham; Adam E Mullick; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-28 Impact factor: 8.311
Authors: Matthew Peach; Ren Xu; Dan Fitzpatrick; Lisa Hamilton; Ransi Somaratne; Robert Scott; Scott M Wasserman; C Stephen Djedjos Journal: J Lipid Res Date: 2016-10-05 Impact factor: 5.922